Business Context and Reporting Period
This Form 8-K filing by Indaptus Therapeutics, Inc. (INDP) was submitted on July 16, 2025, reporting an event that occurred on July 14, 2025. The Company is a Delaware corporation listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material change reported is the resolution of a Nasdaq listing deficiency. Previously notified on January 31, 2025, of non-compliance with the minimum bid price requirement (Rule 5550(a)(2)), the Company successfully regained compliance. Nasdaq confirmed that the closing bid price of the Company's common stock was at least $1.00 per share for 10 consecutive business days from June 27, 2025, to July 11, 2025. Consequently, the prior bid price deficiency matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing status. No unusual items were reported.
Investor Verification Checklist
- Verify the current trading status of INDP on the Nasdaq Capital Market to confirm continued listing.
- Monitor future stock price performance to ensure sustained compliance with the $1.00 minimum bid price requirement.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains no financial metrics.